Allarity Therapeutics, Inc. (ALLR) Key Metrics
ALLR valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $14.2M
- Enterprise value
- $21.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 41.3
- Price / book
- 4.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.57
ALLR key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsALLR returns How much profit the business earns on the capital it uses.
ALLR financial health Debt, liquidity and how easily interest is covered.
ALLR efficiency & capital use Working capital cycle and where the cash goes.
ALLR valuation history
ALLR returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ALLR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ALLR cash returned to shareholders
ALLR price vs earnings per share
ALLR key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $15.5M | — | — | — | — | — | — | — | — | — |
| Enterprise value | $2.2M | — | — | — | — | — | — | — | — | — |
| Price / sales | 48.5 | — | — | — | — | — | — | — | — | — |
| Price / book | 1.6 | — | — | — | — | — | — | — | — | — |
| EV / sales | 7.0 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −72.3% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −95.5% | — | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 20.5% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.08 | $1.17 | $330.66 | $246,792.00 | $8,714,580.00 | — | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.02 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$0.78 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$1.03 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$1.03 | — | — | — | — | — | — | — | — | — |
| Cash per share | $1.02 | — | — | — | — | — | — | — | — | — |
| Book value per share | $0.68 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $0.68 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Debt per share | $0.10 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 14.4M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −103.8% | −541.2% | — | −155.3% | −116.8% | −27.7% | −58.7% | −16.2% | −175.1% | −72.7% |
| Return on invested capital (ROIC) | — | — | — | — | — | −27.0% | −54.7% | −25.9% | — | −116.8% |
| Return on assets (ROA) | −54.9% | −142.1% | −90.1% | −50.0% | −64.2% | −20.3% | −40.8% | −11.3% | −113.5% | −61.4% |
| Return on tangible assets | −61.5% | −108.2% | −597.7% | −321.5% | −124.0% | −226.7% | −365.4% | −101.2% | −234.0% | −82.5% |
| Free cash flow margin | — | — | — | — | — | — | — | −290.6% | −92.2% | — |
| Financial health | ||||||||||
| Total debt | $1.4M | $1.4M | $1.3M | $3.7M | $1.1M | $1.8M | $963,000 | $2.9M | — | — |
| Cash & short-term investments | $14.7M | $19.5M | $166,000 | $2.0M | $19.9M | $298,000 | $1.5M | $237,378 | $536,027 | $2.1M |
| Net debt | −$13.3M | −$18.2M | $1.1M | $1.7M | −$18.8M | $1.5M | −$561,000 | $2.7M | −$536,027 | −$2.1M |
| Debt / equity | 0.14 | 0.11 | — | 1.98 | 0.06 | 0.07 | 0.05 | 0.10 | — | — |
| Debt / assets | 0.08 | 0.06 | 0.11 | 0.26 | 0.02 | 0.05 | 0.03 | 0.08 | — | — |
| Current ratio | 2.13 | 2.06 | 0.14 | 0.44 | 1.03 | 0.31 | 0.71 | 0.41 | 0.77 | 3.27 |
| Quick ratio | 2.13 | 2.06 | 0.14 | 0.44 | 1.10 | 0.31 | 0.71 | 0.41 | 0.67 | 3.24 |
| Interest coverage | -68.1 | -41.7 | -34.4 | -154.5 | -41.5 | -26.0 | -5.3 | -21.4 | — | -102.7 |
| Working capital | $9.5M | $11.5M | −$12.2M | −$6.3M | $685,000 | −$3.8M | −$1.4M | −$3.2M | −$392,915 | $3.0M |
| Invested capital | −$3.5M | −$6.4M | −$1.6M | $3.6M | −$35,000 | $28.3M | $20.3M | $30.6M | −$141,984 | $3.1M |
| Tangible asset value | $9.8M | $11.8M | −$12.6M | −$7.7M | −$9.4M | −$3.6M | −$6.8M | −$8.4M | $394,043 | $3.1M |
| Net current asset value | $9.5M | $11.5M | −$12.6M | −$7.7M | −$9.4M | −$4.8M | −$7.4M | −$8.5M | −$392,915 | $3.0M |
| Graham net-net per share | $0.48 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $11.0M | $1.5M | — | — | — | — | — | — |
| Share buybacks (net) | $3.2M | $3.5M | $6.7M | $1.5M | $0 | — | — | — | — | — |
| Capex / revenue | 2.5% | — | — | — | — | — | 6.7% | 0.4% | 2.5% | 54.3% |
| Capex / depreciation | — | 33.11 | 0.00 | 0.30 | 0.17 | 0.07 | 0.16 | 0.17 | 4.25 | 0.28 |
| Stock-based compensation / revenue | 150.6% | — | — | — | — | — | 277.5% | 14.7% | 159.7% | — |
| R&D / revenue | 2,062.8% | — | — | — | — | — | 5,305.8% | — | — | — |
| SG&A / revenue | 1,976.2% | — | — | — | — | — | 3,225.0% | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 1,781.7 | — | — | — | — | — | 18,910.0 | 1,397.6 | 51.3 | 121.2 |
| Days of inventory on hand | — | — | — | — | -4,631.4 | — | — | — | 16.7 | — |
| Days payables outstanding | — | 255,459.4 | 72,344.0 | 10,568.3 | 4,844.9 | 9,112.3 | — | 86.7 | 143.5 | — |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | 1,310.9 | -75.5 | — |
| Receivables turnover | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.26 | 7.12 | 3.01 |
| Payables turnover | 0.00 | 0.00 | 0.01 | 0.03 | 0.08 | 0.04 | 0.00 | 4.21 | 2.54 | 0.00 |
| Inventory turnover | — | — | — | — | — | — | — | — | 21.81 | 0.00 |
| Asset turnover | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.34 | 0.02 |
| Average receivables | $1.6M | $1.6M | $908,500 | $1.1M | $1.2M | $1.4M | $6.2M | $5.6M | $205,024 | $47,589 |
| Average payables | $4.2M | $6.3M | $7.3M | $3.5M | $1.4M | $2.1M | $2.1M | $1.2M | $873,083 | $1.3M |
| Average inventory | — | — | — | — | −$1.3M | — | −$2,000 | — | $101,796 | $17,348 |
| Intangibles / total assets | 0.0% | 0.0% | 83.2% | 65.7% | 56.7% | 91.3% | 87.6% | 94.1% | 0.0% | 31.7% |
Computed from ALLR's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ALLR valuation and financial ratios
Allarity Therapeutics earned a return on equity of −103.8% in fiscal 2025. It ended the year with $1.4 million of debt and $14.7 million in cash and short-term investments, a net cash position of $13.3 million. It returned $3.2 million to shareholders: $0 in dividends and $3.2 million in share buybacks.
See the ALLR income statement, the ALLR chart for price history, or the ALLR stock overview for the latest quote and news.
ALLR key metrics FAQ
What is Allarity Therapeutics's return on equity?
Allarity Therapeutics's return on equity (ROE) was −103.8% in fiscal 2025: net income of -$11.2 million on average shareholders' equity of $10.8 million.
How much debt does Allarity Therapeutics have?
Allarity Therapeutics had total debt of $1.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.14 and more cash than debt.
Does Allarity Therapeutics buy back its shares?
Yes. Allarity Therapeutics spent $3.2 million on net share repurchases in fiscal 2025.
What is Allarity Therapeutics's free cash flow yield?
Allarity Therapeutics generated -$14.8 million of free cash flow in fiscal 2025, a free cash flow yield of −95.5% on its market value at year-end ($15.5 million).
What is Allarity Therapeutics's current ratio?
Allarity Therapeutics's current ratio was 2.13 at the end of fiscal 2025: current assets were 2.13 times current liabilities.